MARKET

SGEN

SGEN

Seattle Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

116.51
-2.16
-1.82%
After Hours: 116.51 0 0.00% 17:01 04/03 EDT
OPEN
117.25
PREV CLOSE
118.67
HIGH
119.44
LOW
115.94
VOLUME
760.57K
TURNOVER
--
52 WEEK HIGH
124.32
52 WEEK LOW
62.90
MARKET CAP
20.09B
P/E (TTM)
-120.1010
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SGEN stock price target is 126.19 with a high estimate of 165.00 and a low estimate of 95.00.

EPS

SGEN News

More
  • Seattle Genetics Issue Update on Padcev Label Expansion Study
  • Zacks · 23h ago
  • Stock Indexes Jump As Jobless Claims Soar Again
  • Investor's Business Daily · 1d ago
  • Biotech Nears A Breakout As FDA Mulls Speedy Approval For Cancer Drug
  • Investor's Business Daily · 1d ago
  • Seattle Genetics Nears Buy Point
  • Investor's Business Daily Video · 2d ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About SGEN

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
More

Webull offers kinds of Seattle Genetics, Inc. stock information, including NASDAQ:SGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGEN stock news, and many more online research tools to help you make informed decisions.